ALFA Finder| Management target | Revenue 17.5% FY27 |
|---|
| Revenue growth | 24.3% YoY consolidated growth. |
|---|---|
| Margins | Gross margin at 74.1%; EBITDA expanded to 32%. |
| Demand visibility | Strong momentum in preventive and insurance segments. |
| Management confidence | High; citing best-in-class turnaround times and operational efficiency. |
Growth
Standalone revenue rose 26.1%; pathology grew 26%. PAT at INR 51.3 Cr, up 34% YoY.
Outlook
Management maintains mid-to-high teen growth guidance for FY27; divesting radiology business; expansion into Africa.
Risks
Radiology segment remains dilutive to ROC; potential churn in new franchisee additions; pricing erosion in partnership panels.
Last quarter's promises, checked
Delivered
- Guided mid-to-high teen growth → delivered 24.3% (= BEAT)
- Guided 500 franchisees/qtr → delivered 900 (= BEAT)
- Guided 73-74% Gross Margin → delivered 74.1% (= BEAT)
Partly delivered
- Guided 15% volume growth → delivered 28% but with price erosion (= PARTIAL)
Missed
- Guided 34% EBITDA margin → delivered 32.2% (= MISS)
Earnings Call Transcript filed with BSE, NSE: THYROCARE. Summary written with AI assistance from the document.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹490.80
- Market cap
- ₹7,821 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 54.2×Sector 54.5×
- Promoter holding
- 51.02%-9.90% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Other Announcement
Designated person Rahul Guha bought 2,121 Thyrocare shares via market purchase on November 6, 2026, worth ₹0.10 Crore. Post-trade holding is 200,859 shares.
- Value
- ₹0.10 Cr
Thyrocare Technologies Employee Stock Options
Thyrocare allotted 1,94,289 equity shares under its Employee Stock Option Scheme. The allotment lifts paid-up capital to Rs 159.36 crore.
Thyrocare Technologies Management Change
Thyrocare Technologies' Chief Scientific Officer, Dr. Preet Kaur, resigns effective November 6, 2026. The company is identifying a replacement and will disclose details later.
Thyrocare Technologies Other Announcement
Thyrocare disclosed NSE market purchases by an immediate relative and a KMP on 2 November 2026. Combined consideration is about Rs 0.11 Crore, with no promoter involved.
- Value
- ₹0.11 Cr
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare agreed to sell its entire stake in subsidiary Nueclear Healthcare to Trovera. The consideration is about Rs 141.40 Crore, including preference shares and cash.
- Value
- ₹141.4 Cr
Thyrocare Technologies Annual General Meeting
Thyrocare Technologies reported postal ballot voting results approving the purchase of land and building from, and divestment of its entire shareholding in, Nueclear Healthcare Limited.